Press Releases
Date picker
Category
Results per page
Kancera reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study and that Dr. Hanjing Xie has been appointed to Chief Medical Officer
Kancera AB (publ) today reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study, a clinical study of KAND567 in ovarian cancer patients. The company…
Kancera provides operational update for its Fractalkine-blocking drug candidates KAND567 and KAND145
Kancera AB (publ) today reports that the clinical studies of its Fractalkine-blocking drug candidates KAND567 and KAND145 are progressing according to plans and that the US patent office has issued…
Kancera reports that the FRACTAL-study is on track to report top line results in Q3 2023
Kancera AB (publ) reports that 63 subjects have been recruited to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, which exceeds the initial objective of…
Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology
Kancera AB (publ) today announces that it has submitted the regulatory application to the Swedish Medical Products Agency to conduct clinical studies of KAND567 in ovarian cancer and entered into…
Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
This is a translation of the interim report published in Swedish at October 26, 2022
Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies
Kancera AB (publ) reports new preclinical results supporting the potential for KAN571, a ROR1 inhibitor, for treatment of mantle cell lymphoma (MCL), a subtype of B-cell malignancies. Preclinical studies of…
Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma
Regulatory
Kancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such…
Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients
Kancera AB (publ) is today reporting that patient recruitment to the ongoing phase IIa study of KAND567 in myocardial infarction patients is progressing well and 54 patients of the targeted…
Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer
Kancera AB (publ) is today reporting new results that confirm that the company’s Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models…
Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
This is a translation of the interim report published in swedish on Januaryt 19th